

CITATION REPORT

List of articles citing

BACE1 inhibitor drugs in clinical trials for Alzheimer's disease

DOI: 10.1186/s13195-014-0089-7

Alzheimer's Research and Therapy, 2014, 6, 89.

Source: <https://exaly.com/paper-pdf/58439103/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
300	Polyadenylation of nascent RNA during the embryogenesis of <i>Ilyanassa obsoleta</i> . 1975 , 95, 263-8		8
299	Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from <i>Polygonum hydropiper</i> L: a preliminary anti- Alzheimer's study. 2015 , 14, 141		70
298	Expression of β site APP-cleaving enzyme 1 in the hippocampal tissue of an insulin-resistant rat model of Alzheimer's disease. 2015 , 9, 2389-2393		4
297	Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of <i>Drosophila</i> models of Alzheimer's disease. 2015 , 5, 16127		30
296	Lamotrigine Reduces β Site APP-Cleaving Enzyme 1 Protein Levels Through Induction of Autophagy. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 863-76	4.3	16
295	Prospects of β Secretase Inhibitors for the Treatment of Alzheimer's Disease. 2015 , 10, 1463-6		17
294	Camelid heavy chain only antibody fragment domain against β site of amyloid precursor protein cleaving enzyme 1 inhibits β Secretase activity in vitro and in vivo. 2015 , 282, 3618-31		8
293	pH-Dependent Population Shift Regulates BACE1 Activity and Inhibition. 2015 , 137, 9543-6		57
292	Methyl-substitution of an iminohydantoin spiropiperidine β Secretase (BACE-1) inhibitor has a profound effect on its potency. 2015 , 25, 4812-4819		15
291	The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain. 2015 , 135, 1-20		136
290	Protective alleles and modifier variants in human health and disease. 2015 , 16, 689-701		75
289	Effects of BACE1 haploinsufficiency on APP processing and A β concentrations in male and female 5XFAD Alzheimer mice at different disease stages. 2015 , 307, 128-37		20
288	14th Annual Meeting of the Safety Pharmacology Society: Threading through peripheral and central nervous system presentations. 2015 , 75, 143-57		2
287	5-Aryl-1-imino-1-oxo-[1,2,4]thiadiazines. 2015 , 6, 1031-4		1
286	Role of BACE1 in Cognitive Function, from Alzheimer's Disease to Traumatic Brain Injury. 2016 , 239-266		
285	Modulators of Amyloid β Protein (A β) Self-Assembly. 2016 , 97-191		5
284	A Novel Small Molecule Modulator of Amyloid Pathology. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 273-87.3		4

283	Deposition of BACE-1 Protein in the Brains of APP/PS1 Double Transgenic Mice. 2016 , 2016, 8380618		3
282	G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 58	5-3	39
281	BACE1 RNAi Restores the Composition of Phosphatidylethanolamine-Derivates Related to Memory Improvement in Aged 3xTg-AD Mice. <i>Frontiers in Cellular Neuroscience</i> , 2016 , 10, 260	6.1	13
280	One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. 2016 , 10, 177		61
279	Proteomic Substrate Identification for Membrane Proteases in the Brain. 2016 , 9, 96		18
278	Alzheimer's Disease and white matter. 172-184		
277	BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR. <i>PLoS ONE</i> , 2016 , 11, e0149715	3-7	9
276	Proteolytic processing of Neuregulin-1. 2016 , 126, 178-182		25
275	Modern Lead Generation Strategies. 2016 , 13-34		4
274	Presumed LRP1-targeting transport peptide delivers β secretase inhibitor to neurons in vitro with limited efficiency. 2016 , 6, 34297		8
273	3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish". 2016 , 11, 75		73
272	Design and synthesis of 5-cyclopropyl substituted cyclic acylguanidine compounds as BACE1 inhibitors. 2016 , 27, 1626-1629		
271	Determination of the protonation state for the catalytic dyad in β secretase when bound to hydroxyethylamine transition state analogue inhibitors: A molecular dynamics simulation study. 2016 , 66, 155-67		7
270	Alzheimer's therapy targeting the β secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies. 2016 , 126, 183-198		31
269	Synthesis of amino heterocycle aspartyl protease inhibitors. 2016 , 14, 4970-85		8
268	From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease?. 2016 , 59, 7759-70		31
267	A molecular dynamics study of the BACE1 conformational change from Apo to closed form induced by hydroxyethylamine derived compounds. 2016 , 70, 181-195		9
266	Profiling the dynamics of CSF and plasma A β reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. 2016 , 2, 202-212		42

265	Emerging drugs to reduce abnormal β amyloid protein in Alzheimer's disease patients. 2016 , 21, 377-391		43
264	PPAR γ coactivator-1 α gene transfer reduces neuronal loss and amyloid- β generation by reducing β secretase in an Alzheimer's disease model. 2016 , 113, 12292-12297		83
263	Dual Signal Amplification Electrochemical Biosensor for Monitoring the Activity and Inhibition of the Alzheimer's Related Protease β secretase. 2016 , 88, 10559-10565		55
262	Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling. 2016 , 136, 234-49		36
261	A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. 2016 , 291, 19235-44		113
260	Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism. <i>Molecular Psychiatry</i> , 2016 , 21, 1333-41	15.1	28
259	AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1039-1053	4.3	58
258	Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. 2016 , 5, 13		64
257	Drug treatments in Alzheimer's disease. 2016 , 16, 247-53		176
256	Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease. 2016 , 17, 2417-2429		13
255	The road to restoring neural circuits for the treatment of Alzheimer's disease. 2016 , 539, 187-196		280
254	High glucose upregulates BACE1-mediated A β production through ROS-dependent HIF-1 α and LXR β /ABCA1-regulated lipid raft reorganization in SK-N-MC cells. 2016 , 6, 36746		46
253	2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927. 2016 , 26, 1371-1376		3
252	Computational insights into the protonation states of catalytic dyad in BACE1-acyl guanidine based inhibitor complex. 2016 , 70, 226-235		24
251	AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 1109-23	4.3	83
250	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. 2016 , 91, 56-66		178
249	BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides. 2016 , 190, 219-30		34
248	Post-translational regulation of the β secretase BACE1. 2016 , 126, 170-177		17

247	Positive allosteric modulators of $\alpha 7$ nicotinic acetylcholine receptors affect neither the function of other ligand- and voltage-gated ion channels and acetylcholinesterase, nor β amyloid content. 2016 , 76, 19-30	10
246	Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. 2016 , 361, 256-71	89
245	Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography. 2016 , 59, 114-31	94
244	The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease. 2016 , 20, 431-46	64
243	Discovery of polymethoxyflavones from black ginger (<i>Kaempferia parviflora</i>) as potential β secretase (BACE1) inhibitors. 2016 , 20, 567-574	33
242	A Novel Multifunctional Compound Camellikaempferoside B Decreases A β Production, Interferes with A β Aggregation, and Prohibits A β Mediated Neurotoxicity and Neuroinflammation. <i>ACS Chemical Neuroscience</i> , 2016 , 7, 505-18	5-7 22
241	Atorvastatin ameliorates cognitive impairment, A β -42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice. <i>Metabolic Brain Disease</i> , 2016 , 31, 693-703	3-9 11
240	Alzheimer's disease. 2016 , 388, 505-17	1720
239	Constant pH Molecular Dynamics Reveals pH-Modulated Binding of Two Small-Molecule BACE1 Inhibitors. 2016 , 7, 944-9	38
238	Therapeutic strategies for Alzheimer's disease in clinical trials. 2016 , 68, 127-38	298
237	Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease. 2017 , 3, 44-56	21
236	Chronic Sleep Restriction Induces Cognitive Deficits and Cortical Beta-Amyloid Deposition in Mice via BACE1-Antisense Activation. 2017 , 23, 233-240	26
235	BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats. 2017 , 7, 44249	11
234	Marine-Derived Anti-Alzheimer's Agents of Promise. 2017 , 153-184	4
233	Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands. 2017 , 27, 2432-2438	12
232	Galantamine. 2017 , 3, 1	11
231	Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS. 2017 , 9, 813-826	1
230	Development of 2-aminoxazoline 3-azaxanthene β amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D. 2017 , 8, 1196-1206	14

229	BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A β Peptides. 2017 , 57, 1460-1471	32
228	BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from <i>Sargassum serratifolium</i> . 2017 , 25, 3964-3970	30
227	siRNA delivery using polyelectrolyte-gold nanoassemblies in neuronal cells for BACE1 gene silencing. 2017 , 80, 18-28	11
226	Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease. 2017 , 58, 1977-1983	18
225	Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. 2017 , 94, 1056-1070	156
224	Development of a Continuous-Flow Sonogashira Cross-Coupling Protocol using Propyne Gas under Process Intensified Conditions. 2017 , 21, 878-884	17
223	Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor. 2017 , 38, 1260-1269	19
222	Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. 2017 , 140, 898-913	62
221	Selenoprotein S is required for clearance of C99 through endoplasmic reticulum-associated degradation. 2017 , 486, 444-450	11
220	Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases. 2017 , 31, 1029-1041	25
219	Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease. 2017 , 141, 690-702	46
218	Advanced Drug Discovery for Alzheimer's Disease: Challenges and Strategies. 2017 , 9-29	
217	Gene Therapy in the Nervous System: Failures and Successes. 2017 , 1007, 241-257	2
216	Highly Stereoselective Asymmetric Aldol Routes to -Butyl-2-(3,5-difluorophenyl)-1-oxiran-2-yl)ethyl)carbamates: Building Blocks for Novel Protease Inhibitors. 2017 , 58, 4062-4065	4
215	Potent and Selective BACE-1 Peptide Inhibitors Lower Brain A β Levels Mediated by Brain Shuttle Transport. 2017 , 24, 76-92	18
214	A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process. 2017 , 76, 274-288	4
213	BACE1 Deficiency Causes Abnormal Neuronal Clustering in the Dentate Gyrus. 2017 , 9, 217-230	3
212	Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2017 , 74, 126-133	5.1 32

211	Filling the void: a role for exercise-induced BDNF and brain amyloid precursor protein processing. 2017 , 313, R585-R593		9
210	Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. 2017 , 26, 1131-1136		36
209	Coordination compounds of 4,5,6,7-tetrahydro-1H-indazole with Cu(II), Co(II) and Ag(I): structural, antimicrobial, antioxidant and enzyme inhibition studies. 2017 , 70, 4054-4069		14
208	Accurate and Reliable Prediction of the Binding Affinities of Macrocycles to Their Protein Targets. 2017 , 13, 6290-6300		29
207	Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles. 2017 , 187, 1828-1847		6
206	Discovery of imidazopyridines containing isoindoline-1,3-dione framework as a new class of BACE1 inhibitors: Design, synthesis and SAR analysis. 2017 , 138, 729-737		32
205	Full-length cellular β secretase has a trimeric subunit stoichiometry, and its sulfur-rich transmembrane interaction site modulates cytosolic copper compartmentalization. 2017 , 292, 13258-13270		13
204	Orchestration of dynamic copper navigation - new and missing pieces. 2017 , 9, 1204-1229		33
203	Enhanced sleep reverses memory deficits and underlying pathology in Drosophila models of Alzheimer's disease. 2017 , 2, 15-26		28
202	The dual role of thiourea in the thiotrifluoromethylation of alkenes. 2017 , 8, 1195-1199		37
201	Cognitive and Functional Considerations in Alzheimer's Disease Diagnosis. 2017 , 17-26		
200	Therapeutic Potentials of Microalgae in the Treatment of Alzheimer's Disease. <i>Molecules</i> , 2017 , 22,	4.8	61
199	Kinetics and Molecular Docking Studies of 6-Formyl Umbelliferone Isolated from <i>Angelica decursiva</i> as an Inhibitor of Cholinesterase and BACE1. <i>Molecules</i> , 2017 , 22,	4.8	18
198	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. <i>Molecules</i> , 2017 , 22,	4.8	63
197	Amyloid Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease. 2017 , 109-143		5
196	Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 168	5.3	108
195	Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. 2017 , 8, 102		66
194	Physiological Functions of the Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2. 2017 , 10, 97		56

193	Inhibitory effect of ethanol extract of <i>Nannochloropsis oceanica</i> on lipopolysaccharide-induced neuroinflammation, oxidative stress, amyloidogenesis and memory impairment. 2017 , 8, 45517-45530		21
192	PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering A β generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice. 2017 , 8, 81001-81013	62	
191	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease. 2017 , 65-135		1
190	Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease. <i>Journal of Controlled Release</i> , 2018 , 279, 220-233	11.7	45
189	Toward β Secretase-1 Inhibitors with Improved Isoform Selectivity. 2018 , 61, 3491-3502		18
188	Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation. 2018 , 28, 1111-1115		15
187	BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. <i>Journal of Experimental Medicine</i> , 2018 , 215, 927-940	16.6	65
186	Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain. 2018 , 61, 3296-3308		13
185	RAGE mediates A β accumulation in a mouse model of Alzheimer's disease via modulation of β and β Secretase activity. 2018 , 27, 1002-1014		35
184	Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics. 2018 , 7, 233-243		6
183	Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors. 2018 , 28, 2195-2200		8
182	Dual targeting agents for A β plaque/P-glycoprotein and A β plaque/nicotinic acetylcholine α 7* receptors-potential approaches to facilitate A β plaque removal in Alzheimer's disease brain. 2018 , 27, 1634-1646		4
181	Click Chemistry-mediated Biotinylation Reveals a Function for the Protease BACE1 in Modulating the Neuronal Surface Glycoproteome. 2018 , 17, 1487-1501		19
180	Plumbagin ameliorates memory dysfunction in streptozotocin induced Alzheimer's disease via activation of Nrf2/ARE pathway and inhibition of β Secretase. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 101, 379-390	7.5	34
179	Biosynthesis of novel 7,8-dihydroxyflavone glycoside derivatives and in silico study of their effects on BACE1 inhibition. 2018 , 65, 128-137		6
178	Fragment-based virtual screening approach and molecular dynamics simulation studies for identification of BACE1 inhibitor leads. 2018 , 36, 1878-1892		18
177	Population density analysis for determining the protonation state of the catalytic dyad in BACE1-tertiary carbinamine-based inhibitor complex. 2018 , 36, 3557-3574		2
176	Alzheimer's Disease Therapy: Present and Future Molecules. 2018 , 3-22		4

175	Glycyrrhiza uralensis and Semilicoisoflavone B Reduce A β Secretion by Increasing PPAR γ Expression and Inhibiting STAT3 Phosphorylation to Inhibit BACE1 Expression. 2018 , 62, e1700633		9
174	The Role of Glial Cells and Synapse Loss in Mouse Models of Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018 , 12, 473	6.1	11
173	Immunotherapeutic and pharmacological approaches for the treatment of Alzheimer's disease. 2018 , 11,		2
172	Computational Studies Applied to Flavonoids against Alzheimer's and Parkinson's Diseases. 2018 , 2018, 7912765		24
171	Cerebrospinal fluid neurogranin/ β -site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. 2018 , 4, 617-627		17
170	A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β -secretase inhibitors. 2018 , 159, 104-125		5
169	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. 2018 , 18, 847-857		47
168	Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional A β deposition rate and plaque burden at treatment initiation. 2018 , 8, 4957-4968		17
167	A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease. 2018 , 10,		18
166	Insulin Resistance in Alzheimer's Disease. 2018 , 12, 830		94
165	Deletion of aquaporin-4 aggravates brain pathology after blocking of the meningeal lymphatic drainage. 2018 , 143, 83-96		22
164	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. 2018 , 158, 781-800		40
163	Biophenols: Enzymes (β -secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (<i>Olea europaea</i> L.). 2018 , 128, 118-129		33
162	Design, synthesis, X-ray studies, and biological evaluation of novel BACE1 inhibitors with bicyclic isoxazoline carboxamides as the P3 ligand. 2018 , 28, 2605-2610		2
161	Mining of potential drug targets through the identification of essential and analogous enzymes in the genomes of pathogens of <i>Glycine max</i> , <i>Zea mays</i> and <i>Solanum lycopersicum</i> . <i>PLoS ONE</i> , 2018 , 13, e0197511	3.7	1
160	Alzheimer's Disease: Advances in Drug Development. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 3-13	4.3	32
159	Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease. 2018 , 12, 34		25
158	2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. 2018 , 13, 27		105

157	Anti-BACE1 and Antimicrobial Activities of Steroidal Compounds Isolated from Marine Urechis unicinctus. 2018 , 16,		14
156	Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer's Disease. 2018 , 6,		14
155	Comparative Evaluation of the Antioxidant and Anti-Alzheimer's Disease Potential of Coumestrol and Puerarol Isolated from Pueraria lobata Using Molecular Modeling Studies. <i>Molecules</i> , 2018 , 23,	4.8	10
154	BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. <i>PLoS ONE</i> , 2018 , 13, e0200344	3.7	6
153	BACE1 elevation engendered by GGA3 deletion increases β amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice. 2018 , 13, 6		13
152	The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies. 2018 , 14, 1063-1076		55
151	Novel multi-target compounds in the quest for new chemotherapies against Alzheimer's disease: An experimental and theoretical study. 2018 , 26, 4823-4840		6
150	Current understanding of Alzheimer's disease diagnosis and treatment. 2018 , 7,		307
149	The Amyloid- β Oligomer Hypothesis: Beginning of the Third Decade. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S567-S610	4.3	339
148	The effects of alternative splicing on miRNA binding sites in bladder cancer. <i>PLoS ONE</i> , 2018 , 13, e0190798	3.8	10
147	Drug development for Alzheimer's disease: review. 2019 , 27, 164-173		37
146	MicroRNA-200a-3p Mediates Neuroprotection in Alzheimer-Related Deficits and Attenuates Amyloid-Beta Overproduction and Tau Hyperphosphorylation Coregulating BACE1 and PRKACB. 2019 , 10, 806		30
145	Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. 2019 , 33, 883-904		14
144	Flavonoids as Prospective Neuroprotectants and Their Therapeutic Propensity in Aging Associated Neurological Disorders. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 155	5.3	115
143	Acute exercise and brain BACE1 protein content: a time course study. 2019 , 7, e14084		9
142	Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 715-732	4.3	58
141	Functional selection of protease inhibitory antibodies. 2019 , 116, 16314-16319		15
140	Molecular Mechanism of Binding Selectivity of Inhibitors toward BACE1 and BACE2 Revealed by Multiple Short Molecular Dynamics Simulations and Free-Energy Predictions. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 4303-4318	5.7	48

139	Lack of Amyloid cleaving enzyme-1 (BACE1) impairs long-term synaptic plasticity but enhances granule cell excitability and oscillatory activity in the dentate gyrus in vivo. 2019 , 224, 1279-1290		6
138	Dysregulation of stress systems and nitric oxide signaling underlies neuronal dysfunction in Alzheimer's disease. 2019 , 134, 468-483		16
137	Structural, Spectroscopic, Electronic and Molecular Docking Studies on (11R,12 S)-16-Aminotetracyclo[6.6.2.02,7.09,14]hexadeca-2(7),3,5,9(14),10,12-hexaen-15-ol. 2019 , 4, 825-837		1
136	The Alzheimer's Disease-Associated Protein BACE1 Modulates T Cell Activation and Th17 Function. 2019 , 203, 665-675		6
135	Natural Antioxidant Anthocyanins-A Hidden Therapeutic Candidate in Metabolic Disorders with Major Focus in Neurodegeneration. <i>Nutrients</i> , 2019 , 11,	6.7	50
134	A Glycosaminoglycan Extract from Inhibits BACE1, the Secretase Implicated in Alzheimer's Disease. 2019 , 17,		4
133	Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer's disease. 2019 , 9, 590-603		21
132	Non-conventional compounds with potential therapeutic effects against Alzheimer's disease. 2019 , 19, 375-395		9
131	Therapeutic potential of cyanobacterial pigment protein phycoerythrin: in silico and in vitro study of BACE1 interaction and in vivo A β reduction. <i>International Journal of Biological Macromolecules</i> , 2019 , 134, 368-378	7.9	11
130	Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from. <i>Nutrients</i> , 2019 , 11,	6.7	14
129	Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2019 , 87, 474-483	5.1	14
128	A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. 2019 , 33, 251-263		49
127	Hybrid approach to sieve out natural compounds against dual targets in Alzheimer's Disease. 2019 , 9, 3714		2
126	Delivery of BACE1 siRNA mediated by TARBP-BTP fusion protein reduces Amyloid deposits in a transgenic mouse model of Alzheimer's disease. <i>Journal of Biosciences</i> , 2019 , 44, 1	2.3	9
125	Development of Gleevec Analogues for Reducing Production of Amyloid Peptides through Shifting Cleavage of Amyloid Precursor Proteins. 2019 , 62, 3122-3134		3
124	DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells. 2019 , 16, 302-312		6
123	The potential of memory enhancement through modulation of perineuronal nets. 2019 , 176, 3611-3621		9
122	Arylbenzofurans from the Root Bark of as Triple Inhibitors of Cholinesterase, Site Amyloid Precursor Protein Cleaving Enzyme 1, and Glycogen Synthase Kinase-3 Relevance to Alzheimer's Disease. 2019 , 4, 6283-6294		15

121	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated A β 2 Species A β -42. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 2374-2384	5.7	11
120	Identification and Preclinical Evaluation of the Bicyclic Pyrimidine β -Secretase Modulator BMS-932481. 2019 , 10, 312-317		10
119	Pharmacological Interventions to Attenuate Alzheimer's Disease Progression: The Story So Far. <i>Current Alzheimer Research</i> , 2019 , 16, 261-277	3	19
118	Mitigating Alzheimer's Disease with Natural Polyphenols: A Review. <i>Current Alzheimer Research</i> , 2019 , 16, 529-543	3	27
117	Phytoconstituent plumbagin: Chemical, biotechnological and pharmaceutical aspects. <i>Studies in Natural Products Chemistry</i> , 2019 , 63, 415-460	1.5	2
116	BACE1 partial deletion induces synaptic plasticity deficit in adult mice. 2019 , 9, 19877		10
115	Sez6 levels are elevated in cerebrospinal fluid of patients with inflammatory pain-associated conditions. 2019 , 4, e719		4
114	Application of molecular framework-based data-mining method in the search for beta-secretase 1 inhibitors through drug repurposing. 2019 , 37, 3674-3685		12
113	Acylguanidine-BACE1 complex: Insights of intermolecular interactions and dynamics. 2019 , 464, 33-49		9
112	Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. 2019 , 195, 186-198		77
111	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. <i>Journal of Experimental Medicine</i> , 2019 , 216, 279-293	16.6	35
110	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. 2019 , 15, 55-64		50
109	Quantitative Analysis of F-PF-06684511, a Novel PET Radioligand for Selective β -Secretase 1 Imaging, in Nonhuman Primate Brain. 2019 , 60, 992-997		5
108	Fucosterol exerts protection against amyloid β -induced neurotoxicity, reduces intracellular levels of amyloid β and enhances the mRNA expression of neuroglobin in amyloid β -induced SH-SY5Y cells. <i>International Journal of Biological Macromolecules</i> , 2019 , 121, 207-213	7.9	18
107	Protein aggregation in cell biology: An aggregomics perspective of health and disease. 2020 , 99, 40-54		21
106	Discovery of AM-6494: A Potent and Orally Efficacious β -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2. 2020 , 63, 2263-2281		19
105	A combinational treatment of carotenoids decreases A β secretion in human neurons via β -Secretase inhibition. 2020 , 158, 47-55		4
104	Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat. 2020 , 60, 107-116		4

103	BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2020 , 40, 339-384	14.4	90
102	Synthesis of a carbon-11 radiolabeled BACE1 inhibitor. 2020 , 29, 262-267		
101	In silico discovery of noteworthy multi-targeted acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. 2020 , 20, 351-366		2
100	4-Substituted 2-amino-3,4-dihydroquinazolines with a 3-hairpin turn side chain as novel inhibitors of BACE-1. <i>Bioorganic Chemistry</i> , 2020 , 95, 103135	5.1	3
99	Scope of β -Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 3510-3522	5.7	6
98	Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy. <i>Science Advances</i> , 2020 , 6,	14.3	45
97	Flavonoids as BACE1 inhibitors: QSAR modelling, screening and in vitro evaluation. <i>International Journal of Biological Macromolecules</i> , 2020 , 165, 1323-1330	7.9	5
96	Surface Modification of Iron Oxide-Based Magnetic Nanoparticles for Cerebral Theranostics: Application and Prospection. <i>Nanomaterials</i> , 2020 , 10,	5.4	17
95	The botanical origin and antioxidant, anti-BACE1 and antiproliferative properties of bee pollen from different regions of South Korea. <i>BMC Complementary Medicine and Therapies</i> , 2020 , 20, 236	2.9	4
94	Prediction of Drug Potencies of BACE1 Inhibitors: A Molecular Dynamics Simulation and MM_GB(PB)SA Scoring. <i>Computation</i> , 2020 , 8, 106	2.2	2
93	BACE1 Inhibitor, Neuroprotective, and Neurotogenic Activities of Melatonin Derivatives. <i>Scientia Pharmaceutica</i> , 2020 , 88, 58	4.3	2
92	Correlation of Serum BACE1 With Emergence Delirium in Postoperative Patients: A Preliminary Study. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 555594	5.3	0
91	A novel phytochemical from <i>Dipteris wallichii</i> inhibits human β -Secretase 1: Implications for the treatment of Alzheimer's disease. <i>Medical Hypotheses</i> , 2020 , 143, 109839	3.8	3
90	Popular three-dimensional models: Advantages for cancer, Alzheimer's and cardiovascular diseases. <i>Tissue and Cell</i> , 2020 , 65, 101367	2.7	
89	Trehalose against Alzheimer's Disease: Insights into a Potential Therapy. <i>BioEssays</i> , 2020 , 42, e1900195	4.1	14
88	A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β -Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and HO-Induced Cytotoxicity in SH-SY5Y Cells. <i>Neurochemical Research</i> , 2020 , 45, 2113-2127	4.6	0
87	MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Open Access Journal of Clinical Trials</i> , 2020 , 12, 1-13	1.5	14
86	New BACE1 Chimeric Peptide Inhibitors Selectively Prevent APP-Cleavage Decreasing Amyloid- β Production and Accumulation in Alzheimer's Disease Models. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 1317-1337	4.3	4

85	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. <i>Molecular Psychiatry</i> , 2020 ,	15.1	30
84	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. <i>Medicinal Research Reviews</i> , 2021 , 41, 2689-2745	14.4	3
83	Amyloid Beta. 2021 , 1-17		
82	Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021 , 13, e1696	9.2	1
81	Metabolic disorder in Alzheimer's disease. <i>Metabolic Brain Disease</i> , 2021 , 36, 781-813	3.9	3
80	Therapeutic Strategies Targeting Amyloid- β Receptors and Transporters in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 1429-1442	4.3	3
79	The Neurovascular Unit Dysfunction in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	25
78	Activation of CREB-mediated autophagy by thioperamide ameliorates β amyloid pathology and cognition in Alzheimer's disease. <i>Aging Cell</i> , 2021 , 20, e13333	9.9	6
77	Preclinical validation of a potent β secretase modulator for Alzheimer's disease prevention. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	22
76	HIV-1 Natural Antisense Transcription and Its Role in Viral Persistence. <i>Viruses</i> , 2021 , 13,	6.2	2
75	Examination of BDNF Treatment on BACE1 Activity and Acute Exercise on Brain BDNF Signaling. <i>Frontiers in Cellular Neuroscience</i> , 2021 , 15, 665867	6.1	1
74	In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021 , 24, 729-736	1.3	1
73	Alzheimer's Disease: Innovative Therapeutic Approaches Based on Peptides and Nanoparticles. <i>Neuroscientist</i> , 2021 , 10738584211016409	7.6	0
72	Beta-Secretase 1 Underlies Reactive Astrocytes and Endothelial Disruption in Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2021 , 15, 656832	6.1	4
71	An Overview of β Amyloid Cleaving Enzyme 1 (Bace1) in Alzheimer's Disease Therapy Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor. <i>Current Medicinal Chemistry</i> , 2021 ,	4.3	2
70	Dietary Spray-Dried Porcine Plasma Reduces Neuropathological Alzheimer's Disease Hallmarks in SAMP8 Mice. <i>Nutrients</i> , 2021 , 13,	6.7	3
69	Identification of novel A β 1rB2 inhibitors as potential therapeutic agents for Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2021 , 114, 103630	4.8	0
68	Antioxidative and Anti-inflammatory Effects of Kojic Acid in A β Induced Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021 , 58, 5127-5140	6.2	13

67	Acetylcholine esterase inhibitory activity of green synthesized nanosilver by naphthopyrones isolated from marine-derived <i>Aspergillus niger</i> . <i>PLoS ONE</i> , 2021 , 16, e0257071	3.7	1
66	Role of amber extract in protecting SHSY5Y cells against amyloid β -42-induced neurotoxicity. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 141, 111804	7.5	1
65	Lin_F9: A Linear Empirical Scoring Function for Protein-Ligand Docking. <i>Journal of Chemical Information and Modeling</i> , 2021 , 61, 4630-4644	6.1	2
64	GSK-3 β as a target for apigenin-induced neuroprotection against A β 25-35 in a rat model of Alzheimer's disease. <i>Neuropeptides</i> , 2021 , 90, 102200	3.3	3
63	Naphthalene Monoimide Derivative Ameliorates Amyloid Burden and Cognitive Decline in a Transgenic Mouse Model of Alzheimer's Disease. <i>Advanced Therapeutics</i> , 2021 , 4, 2000225	4.9	6
62	Review of the Pathology, Diagnosis and Treatment for Alzheimer's Disease. 2021 ,		
61	Lipids, beta-secretase 1, and Alzheimer disease. 2021 , 289-299		
60	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain		1
59	BACE1 Regulates Proliferation and Neuronal Differentiation of Newborn Cells in the Adult Hippocampus in Mice. <i>ENeuro</i> , 2018 , 5,	3.9	14
58	Partial, Rather than Full, BACE1 Inhibition May Be a Better Therapeutic Strategy for Alzheimer's Disease Due to Effects of Complete Loss of BACE1 Activity on Adult Hippocampal Neurogenesis. <i>ENeuro</i> , 2018 , 5,	3.9	1
57	Alzheimer's disease: amyloid-based pathogenesis and potential therapies. <i>Cell Stress</i> , 2018 , 2, 150-161	5.5	11
56	Effects of senescence and angiotensin II on expression and processing of amyloid precursor protein in human cerebral microvascular endothelial cells. <i>Aging</i> , 2018 , 10, 100-114	5.6	8
55	Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2017 , 14, 412-425	3	147
54	Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross-Sectional Study. <i>Current Alzheimer Research</i> , 2020 , 17, 355-364	3	4
53	Recent Studies on Design and Development of Drugs Against Alzheimer's Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 1195-1213	3	4
52	In Silico Inhibition of BACE-1 by Selective Phytochemicals as Novel Potential Inhibitors: Molecular Docking and DFT Studies. <i>Current Drug Discovery Technologies</i> , 2020 , 17, 397-411	1.5	16
51	Synthesis and In Vitro Biological Activity Evaluation of Novel Imidazo [2,1-B][1,3,4] Thiadiazole as Anti-Alzheimer Agents. <i>Letters in Drug Design and Discovery</i> , 2020 , 17, 610-617	0.8	1
50	Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, A β PP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow. 2020 , 2, 90-114		4

49	Drugs and drug delivery systems targeting amyloid- β in Alzheimer's disease. <i>AIMS Molecular Science</i> , 2015 , 2, 332-358	0.9	16
48	Extracellular-Signal-Regulated Kinase Inhibition Switches APP Processing from β to β Secretase under Oxidative Stress: Modulation of ADAM10 by SIRT1/NF- κ B Signaling. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 4175-4186	5.7	2
47	A Network-based Deep Learning Framework Catalyzes GWAS and Multi-Omics Findings to Biology and Drug Repurposing for Alzheimer's Disease.		
46	A common strategy to improve transmembrane transport in polarized epithelial cells based on sorting signals: Guiding nanocarriers to TGN rather than to the basolateral plasma membrane directly. <i>Journal of Controlled Release</i> , 2021 , 339, 430-444	11.7	1
45	Delivery of BACE1 siRNA mediated by TARBP-BTP fusion protein reduces β amyloid deposits in a transgenic mouse model of Alzheimer's Disease.		
44	Verubecestat. 2017 , 204-251		
43	DECODER: A probabilistic approach to integrate big data reveals mitochondrial Complex I as a potential therapeutic target for Alzheimer's disease.		1
42	Amyloid Beta. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2019 , 235-251	0.2	1
41	Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia. <i>Open Journal of Medicinal Chemistry</i> , 2019 , 09, 1-35	0.1	1
40	A Novel Cell-based β Secretase Enzymatic Assay for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019 , 16, 128-134	3	
39	Therapeutic Targeting of Casein Kinase 1 γ in an Alzheimer's Disease Mouse Model.		
38	AD "Statin": Alzheimer's Disorder is a "Fast" Disease Preventable by Therapeutic Intervention Initiated Even Late in Life and Reversible at the Early Stages. 2020 , 2, 75-89		3
37	A glycosaminoglycan extract from <i>Portunus pelagicus</i> inhibits BACE1, the β Secretase implicated in Alzheimer's disease.		
36	Alzheimer's disease and its current treatments; Is there a possibility for a cure?. <i>Open Journal of Chemistry</i> , 2019 , 5, 013-019	0.4	2
35	Contributing Factors of Neurodegeneration in Alzheimer's Disease. 69-84		
34	All-trans retinoic acid in Alzheimer's disease. 2020 , 559-572		
33	Naphthalene monoimide derivative ameliorates amyloid burden and cognitive decline in a transgenic mouse model of Alzheimer's disease.		
32	Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020 , 19, 709-721	2.6	2

31 Changing fate. **2020**, 617-630

30 Natural products as anti-Alzheimer's drugs. *Studies in Natural Products Chemistry*, **2020**, 66, 157-174 1.5

29 COMPUTER AIDED DRUG DESIGN: A PARADIGM SHIFT TO RATIONAL DRUG DESIGN (A CASE STUDY OF ALZHEIMER'S DRUG INTERPIRDINE FAILURE). *International Journal of Engineering Technologies and Management Research*, **2017**, 4, 13-18 0.1

28 An Insight into the Potential Application of Microalgae in Pharmaceutical and Nutraceutical Production. **2021**, 135-179 3

27 Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. *Yale Journal of Biology and Medicine*, **2016**, 89, 5-21 2.4 57

26 Protein-Encoding RNA-to-RNA Information Transfer in Mammalian Cells: Principles of RNA-Dependent mRNA Amplification. **2019**, 1, 6

25 Protein-Encoding RNA to RNA Information Transfer in Mammalian Cells: RNA-dependent mRNA Amplification. Identification of Chimeric RNA Intermediates and Putative RNA End Products. **2019**, 1, 23-47 6

24 Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent APP mRNA Amplification. An Engine that Drives Alzheimer's Disease. **2019**, 1, 61-74 3

23 Beyond structural analysis of molecular enzyme-inhibitor interactions. *Electronic Structure*, 2.6 1

22 Esculentoside A alleviates cognitive deficits and amyloid pathology through peroxisome proliferator-activated receptor dependent mechanism in an Alzheimer's disease model.. *Phytomedicine*, **2022**, 98, 153956 6.5 2

21 Aminoimidazo[1,2-a]pyridine Bearing Different Pyrazole Moieties as the Structural Scaffold for the Development of BACE1 Inhibitor; Synthesis, Structural Characterization, In vitro and In silico Studies.. *Current Organic Synthesis*, **2022**, 1.9

20 Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer's disease.. *IScience*, **2022**, 25, 103869 6.1 1

19 Delivery of BACE1 siRNA mediated by TARBP-BTP fusion protein reduces amyloid deposits in a transgenic mouse model of Alzheimer's disease. *Journal of Biosciences*, **2019**, 44, 2.3 6

18 In silico screening of potential secretase (BACE1) inhibitors from VIETHERB database.. *Journal of Molecular Modeling*, **2022**, 28, 60 2

17 Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management.. *Computers in Biology and Medicine*, **2022**, 145, 105422 7

16 Data_Sheet_1.DOCX. **2018**,

15 Table_1.DOCX. **2020**,

14 Presentation_1.pdf. **2019**,

13	In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy.. <i>Molecules</i> , 2022 , 27,	4.8	3
12	Delta Machine Learning to Improve Scoring-Ranking-Screening Performances of Protein-Ligand Scoring Functions.. <i>Journal of Chemical Information and Modeling</i> , 2022 ,	6.1	3
11	DHA Ameliorates Cognitive Ability, Reduces Amyloid Deposition, and Nerve Fiber Production in Alzheimer's Disease. <i>Frontiers in Nutrition</i> , 9,	6.2	0
10	Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amyloid load in Alzheimer's disease.		0
9	Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology. 2022 , 27, 4839		0
8	Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. 2022 , 23, 9305		0
7	The metabolism of human soluble amyloid precursor protein isoforms is quantifiable by a stable isotope labeling-tandem mass spectrometry method. 2022 , 12,		0
6	Deciphering the Molecular Mechanism of Inhibition of β Secretase (BACE1) Activity by a 2-Amino-imidazol-4-one Derivative. 2022 , 7,		1
5	Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review. 2022 , 74, 117047		1
4	Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease. 2022 , 41, 111717		0
3	Drug Discovery To Drug Development Of Bace1 Inhibitor As Anti-Alzheimer's: A Review. 2022 , 23,		0
2	Molecular Mechanisms of Emerging Therapeutic Targets in Alzheimer's Disease: A Systematic Review. 2022 , 16, 443-455		0
1	Acute interleukin-6 modulates key enzymes involved in prefrontal cortex and hippocampal amyloid precursor protein processing. 2023 , 134, 1115-1123		0